Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus

International Journal of Cancer

Volumn 128, Issue 10, 2011, Pages 2495-2500

  Frenzel, Lukas P ^a,b   Claus, Rainer ^c   Plume, Nadine ^a   Schwamb, Janine ^a,b   Konermann, Carolin ^c   Pallasch, Christian P ^a,b,d   Claasen, Julia ^a,b   Brinker, Reinhild ^a,b   Wollnik, Bernd ^a   Plass, Christoph ^c   Wendtner, Clemens Martin ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

A20; CLL; methylation; NF kappa B; TNFAIP3

Indexed keywords

A20 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UBIQUITIN; UNCLASSIFIED DRUG;

A20 ONCOGENE; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETICS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

CHROMOSOMES, HUMAN, PAIR 6; DNA METHYLATION; EPIGENESIS, GENETIC; EXONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NF-KAPPA B; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC;

EID: 79953212966     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25579     Document Type: Article

References (25)

1. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, Hallek M, Wendtner CM,. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742-51. (Pubitemid 43076401)
2. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, Sullivan K, Vijayakrishnan J, Wang Y, Pittman AM, Sunter NJ, Hall AG, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008; 40: 1204-10.
3. Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859-61. (Pubitemid 43156279)
4. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R, Fegan C, Brennan P, Pepper C,. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009; 27: 763-9.
5. Pepper C, Hewamana S, Brennan P, Fegan C,. NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 2009; 5: 1027-37.
6. Coornaert B, Carpentier I, Beyaert R,. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009; 284: 8217-21.
7. Song HY, Rothe M, Goeddel DV,. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation. Proc Natl Acad Sci U S A 1996; 93: 6721-5. (Pubitemid 26230376)
8. Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O, McNally E, Pickart C, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004; 5: 1052-60. (Pubitemid 41057725)
9. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-9. (Pubitemid 39061687)
10. Shembade N, Ma A, Harhaj EW,. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science 2010; 327: 1135-9.
11. Vereecke L, Beyaert R, van Loo G,. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009; 30: 383-91.
12. Kato M, Sanada M, Kato I, Sato Y, Takita J, Takeuchi K, Niwa A, Chen Y, Nakazaki K, Nomoto J, Asakura Y, Muto S, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature 2009; 459: 712-6.
13. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-21.
14. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, Cerri M, Rossi D, Murty VV, Zucca E, Gaidano G, Dalla-Favera R, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009; 113: 4918-21.
15. Schmitz R, Hansmann ML, Bohle V, Martin-Subero JI, Hartmann S, Mechtersheimer G, Klapper W, Vater I, Giefing M, Gesk S, Stanelle J, Siebert R, et al. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009; 206: 981-9.
16. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, Seto M,. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009; 114: 2467-75.
17. Chanudet E, Huang Y, Ichimura K, Dong G, Hamoudi RA, Radford J, Wotherspoon AC, Isaacson PG, Ferry J, Du MQ,. A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010; 24: 483-7.
18. Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H, Ultsch A, Wickenhauser C, Hallek M, Wendtner CM,. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112: 4213-9.
19. Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, et al. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 2009; 114: 3255-64.
20. Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R, Rehli M,. Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res 2006; 66: 6118-28.
21. Schilling E, Rehli M,. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 2007; 90: 314-23. (Pubitemid 47176332)
22. Ehrich M, Nelson MR, Stanssens P, Zabeau M, Liloglou T, Xinarianos G, Cantor CR, Field JK, van den Boom D,. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A 2005; 102: 15785-90. (Pubitemid 41552820)
23. Emmerich F, Meiser M, Hummel M, Demel G, Foss HD, Jundt F, Mathas S, Krappmann D, Scheidereit C, Stein H, Dorken B,. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999; 94: 3129-34. (Pubitemid 29512720)
24. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008; 319: 1676-9. (Pubitemid 351432507)
25. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM, Dohner H, Heimpel H,. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002; 100: 3749-56. (Pubitemid 35303947)